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Methods: The 21-month longitudinal study included 159 subjects
prospectively selected as representative for the general population. From
these, only those over 30 years at follow-up were included to ensure a
homogeneous population. In total, 123 completed the study, age 58±14,
BMI 26±4, 47% female, and 54% with OA (Kellgren and Lawrence,
KL 1). Radiographs were acquired in a load-bearing semi-ﬂexed po-
sition using the SynaFlex (Synarc) and joint space width (JSW) was
measured. MRI scans with near-isotropic voxels were acquired from a
Turbo 3D T1 sequence from a 0.18T Esaote scanner (40º FA, TR 50ms,
TE 16ms, scan time 10 minutes, resolution 0.7mm×0.7mm×0.8mm)
and markers for volume, thickness, smoothness, homogeneity, and cur-
vature were quantiﬁed in a fully automatic computer-based framework.
Bone resorption was measured by the biochemical marker serum CTX-I
(C-terminal telopeptide of collagen type I) and cartilage degradation by
urine CTX-II (collagen type II, sample acquired as second morning void).
Pain was quantiﬁed by a visual assessment scale (VAS). Radiograph and
MRI markers were averaged for left and right medial compartments and
MRI markers were the sum of tibial and femoral compartments. Cross-
sectional biomarker scores and longitudinal changes over 21 months
were tested for association with pain and evaluated by correlation (r),
t-test of whether scores are higher in the group with pain (p), and odds
ratio for high scores relating to pain (OR).
Results: For all markers, the results are listed in Table 1. Cross-
sectionally at follow-up, BMI and CTX-II were associated with pain,
whereas age, JSW and homogeneity were borderline associated. Lon-
gitudinally, the changes from baseline to follow-up were borderline asso-
ciated with pain at follow-up for homogeneity and CTX-II. For CTX-II and
homogeneity this persisted after linear correction for gender and age (GA
cor).
Biomarker associations with pain, cross-sectional (C) and longitudinal (L)
r (C) p (C) OR (C) r (L) p (L) OR (L)
Age 0.21 0.053 3.8 *
Gender 0.02 0.445 1.4
BMI 0.26* 0.021* 3.3* −0.10 0.288 1.9
JSW −0.19 0.062 3.1* −0.09 0.737 1.2
CTX-I −0.16 0.028* 2.9 0.09 0.129 2.3
CTX-II 0.29** 0.001** 7.1** 0.05 0.077 3.2*
Volume −0.13 0.681 1.5 −0.16 0.063 2.3
Thickness −0.19 0.425 1.3 −0.14 0.866 0.9
Smoothness −0.13 0.936 0.9 −0.05 1.000 1.1
Homogeneity 0.22* 0.090 2.3 0.20 0.043* 3.3*
Curvature −0.02 0.549 1.4 0.06 0.973 0.7
CTX-II (GA cor) 0.28* 0.003** 7.1* 0.05 0.077 3.2*
Hom. (GA cor) 0.23* 0.099 2.3 0.20 0.043* 3.3*
Conclusions: The results in this study indicated that pain was associated
with the biochemical marker for cartilage breakdown (CTX-II) rather
than bone turnover (CTX-I). Furthermore, pain was associated with
the cartilage marker related to internal structure (homogeneity) rather
than denudation (volume or thickness). Combined, these results may
indicate that early stage cartilage breakdown should not be ignored
by treatment development targeting pain prevention. Measurement of
pain in longitudinal clinical studies is challenging due to poor precision
and confounding effects. Therefore, the cross-sectional and longitudinal
associations between pain and cartilage homogeneity (that has inter-scan
RMS CV 1.0%) merits further research to reveal whether homogeneity
may be a suitable surrogate marker for pain.
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Purpose: Altered subchondral bone remodeling and structure have been
suggested to play a role in the development of osteoarthritis (OA). Recent
animal studies have shown progressive articular cartilage degradation
in a mouse model of osteogenesis imperfecta (OI), a disease caused
by mutations in type I collagen (Col I) genes which are associated with
abnormal bone matrix. The aim of this study was to investigate whether
adult patients with OI used as a human model of bone Col-I defect, are
characterized by increased cartilage type II collagen (Col-II) degradation.
Methods: Sixty four patients with mild OI (25 women, 39 men; mean
age (SD): 36.2 (11.6) year) participating in a randomized study and 64
sex and age matched healthy controls were included. In patients with OI
and controls, we assessed the following bone Col-I and cartilage Col-II
parameters using speciﬁc biochemical markers: (1) Col I synthesis by
serum N-propeptide (PINP), (2) Col-I degradation by urinary fragments
of the helical domain of Col-I (Helix-I), (3) Col-I maturation by the
urinary ratio of native (a CTX-I) to isomerized (b CTX-I) aspartic acid
of Col-I C-telopeptide (a/b CTX-I). Isomerization is a post-translational
modiﬁcation of Col I reﬂecting the degree of bone matrix maturation
which has shown to be associated with altered structure, a high urinary
a/b CTX-I ratio being indicative of lower bone matrix maturation and
(4) Col-II degradation by urinary C-terminal telopeptide fragments (CTX-
II).
Results: As shown on the table, compared to healthy controls, adults
with OI had signiﬁcantly decreased bone Col-I synthesis (lower PINP),
increased bone Col-I degradation (higher Helix-I), decreased bone Col-I
maturation (higher a/b CTX-I ratio) and a marked increase in cartilage Col-
II degradation (high CTX-II). In patients with OI, urinary CTX-II correlated
with Helix-I, (r = 0.48, <0.0001) suggesting an association between bone
Col I and cartilage Col II degradation.
Conclusions: Cartilage type II collagen degradation is increased in a
human model of bone type I collagen defect. These data are in agreement
with animal studies suggesting that altered subchondral bone remodeling
and structure may be involved in the development of OA.
Subjects PINP
(ng/ml)
Helix-I
(mg/mmol Cr)
a/b CTX-I CTX-II
(ng/mmol Cr)
OI (n = 64) 32.3±19.8* 67.7±40.0* 2.04±0.72* 460±576*
Controls (n = 64) 41.8±13.5 42.8±19.4 1.37±0.43 143±62
*p< 0.001 vs controls; results are means±SD.
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Purpose: The molecular changes that occur in the early stages of
osteoarthritis (OA) are poorly understood. The aim of this study was to
use a targeted proteomic approach aimed at identiﬁcation of secreted
biomarkers from equine cartilage explants stimulated with recombinant
equine interleukin-1 beta (Il-1b).
Methods: Equine articular cartilage was obtained from weight bearing
regions of metatarsophalangeal joints of horses euthanized for purposes
other than for research. Full depth cartilage discs were excised with a
biopsy punch and washed extensively in PBS and serum free DMEM.
Explants were either incubated alone (control), or with Il-1b (10 ng×ml−1)
at 37ºC for 5 days. Supernatants were then removed and frozen before
trypsin digestion overnight at 37ºC. The reaction was stopped with formic
acid and the samples were stored at −80ºC until proteomic analysis by
ESI (Electrospray Ionisation) mass spectrometry. Peptides were sepa-
rated on a C18 pepmap column using a Dionex U3000 chromatography
platform and detected in a Bruker HCT PTM discovery ion trap instrument.
The four most abundant peptides in each MS scan were selected for
fragmentation. Using MASCOT search engine the fragment patterns
for each were compared to the mammalian entries in the SwissProt
database. The modiﬁcations incorporated into the search were: ﬁxed
carbamidomethyl cysteine, variable oxidation of methionine and variable
deamidation of asparagine and glutamine residues.
Results: Comparative proteomic analysis of the supernatants identiﬁed
a number of relevant proteins. Tryptic peptides originating from aggrecan
core protein, cartilage oligomeric matrix protein (COMP), ﬁbronectin,
ﬁbromodulin, thrombospondin-1 (TSP-1) and matrix metalloproteinases
MMP-1 and MMP-3 were detected. Several novel and unexpected se-
creted proteins were also identiﬁed including clusterin, cartilage interme-
diate layer protein-1 (CILP-1) and chondroadherin (CHAD) precursor.
Conclusions: This study has highlighted the presence of several novel
biomarkers in the supernatants of cartilage explants stimulated with Il-1b.
Many of the identiﬁed proteins have putative matrix functions including
participation in cell-matrix and matrix-matrix interactions (i.e. ﬁbronectin,
TSP-1, COMP, CHAD), matrix turnover (MMP-1, MMP-3) and extracellular
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molecular chaperone activity (clusterin). Interestingly, other proteomic
studies have identiﬁed clusterin and CILP-1 as being upregulated in early
human OA. These biomarkers may be involved in early repair responses
in cartilage and thus may be useful for the detection of early changes in
OA.
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Purpose: Ephrin is well documented in the literature for its functions in
the nervous and cardiovascular systems. However, it has recently been
shown that the interaction of the EphB4 receptor with its speciﬁc ligand
ephrin B2 could be implicated in the physiological regulation of bone
homeostasis. Osteoarthritis (OA), although characterized by cartilage
breakdown and inﬂammation of the synovial membrane, also demon-
strates important changes in the subchondral bone. Recent studies have
shown that an abnormal remodeling process of this tissue is intimately
involved in the genesis of OA. We recently classiﬁed human OA sub-
chondral bone osteoblasts into two subgroups according to their low (L)
or high (H) PGE2 levels. Further data demonstrated that the L-OA showed
bone pro-resorption activities and the H-OA pro-formation properties. In
this study we determined the presence, level and modulation of EphB4
receptors on each of these subgroups. Further, we investigated the
modulation of EphB4 receptors and the effect of their activation by ephrin
B2 on OA osteoblasts.
Methods: The in situ presence of EphB4 receptors in the subchondral
bone was determined by immunohistochemistry. The EphB4 receptor
expression level, modulation upon treatment with osteotropic factors,
and effect of activation by ephrin B2 on bone catabolic mediators were
determined using real-time PCR. The ephrin B2-activated EphB4 receptor
effect on the bone resorption activity was also determined using a co-
culture system of differentiated human PBMC and human subchondral
bone osteoblasts. The intra-cellular signaling pathways employed by the
EphB4 receptor activation were investigated by speciﬁc ELISA.
Results: Data showed that EphB4 receptors were present in the human
subchondral bone osteoblasts and osteocytes. A signiﬁcant increase in
EphB4 receptor expression level was found in the L-OA osteoblasts
compared to the normal (p< 0.002) and the H-OA (p< 0.0007). However,
there was no difference between the normal and the H-OA. EphB4
receptor levels in the L-OA osteoblasts were signiﬁcantly up-regulated
by PGE2 and Il-17. Interestingly, ephrin B2, PGE2 and Il-17 signiﬁcantly
inhibited the bone resorption activity in L-OA osteoblasts. EphB4 ac-
tivation by ephrin B2 signiﬁcantly inhibited the expression level of the
pro-inﬂammatory cytokines Il-1b and Il-6, the metalloproteases MMP-1,
MMP-9 and MMP-13, as well as RANKL. The factors MMP-2 and OPG
were not modulated. The EphB4 receptor activation signiﬁcantly reduced
the PI3K/Akt pathway, but had no signiﬁcant effect on the MAP kinases.
Conclusions: This study, for the ﬁrst time, provides evidence that EphB4
receptor activation by ephrin B2 in human OA subchondral bone could
impact abnormal metabolism in this tissue by inhibiting resorption factors
and their activities. The differential level of EphB4 receptors in the L-OA
and H-OA subchondral bone osteoblasts also indicates that these cells
have reached a different pathological stage. Data from this study bring to
light that ephrin B2 could be targeted as a speciﬁc therapeutic approach
in the development of a disease modifying OA drug, as this factor could
exert a protective effect on OA articular tissue structural changes.
A42 A GENOME-WIDE ASSOCIATION STUDY REVEALS A NOVEL
LOCUS FOR HAND OSTEOARTHRITIS
G. Zhai1, J.B. van Meurs2, A.M. Valdes1, D. Hart1, G. Livshits3,
M. Inouye4, N. Soranzo4, P. Deloukas4, A. Uitterlinden2, T.D. Spector1.
1King’s College London, London, UNITED KINGDOM, 2Erasmus MC,
Rotterdam, NETHERLANDS, 3Sackler Faculty of Medicine, Tel Aviv,
ISRAEL, 4The Wellcome Trust Sanger Institute, Cambridge, UNITED
KINGDOM
Purpose: Although a signiﬁcant genetic effect on hand osteoarthritis (OA)
has been reported, conﬁrmed replicated genetic factors have not yet been
identiﬁed. The aim of this study, therefore, was to identify speciﬁc genetic
polymorphisms for hand OA by means of the genome-wide association
study (GWAS) in Caucasian population.
Methods: A three stage approach was utilized. First, we conducted
a GWAS implementing 317,818 SNPs across the entire genome in
651 women of the North European origin from the TwinsUK registry. Next,
we tested the top 100 SNPs identiﬁed in our GWAS in the Rotterdam
cohort, consisting of 1438 men and women aged over 50. In the ﬁnal
stage, we searched for conﬁrmation of the association between the OA
and SNPs that showed the most signiﬁcant association results in the
second stage. To this aim we used additional independent population-
based sample – the Chingford Study, including 671 British women. All
participants in the study had their both hands X-rayed, and 15 joints on
each hand (DIP, PIP, MCP, and ﬁrst CMC) were scored for OA, using
Kellgren-Lawrence (KL) system. The total KL score adjusted for age (and
sex) was used in the analysis.
Results: We identiﬁed replicated evidence of an association between
the SNP which is located in chromosome16p13 and hand OA. The minor
allele with a frequency of 32% signiﬁcantly decreased (b=−0.16±0.03
SE) the total KL score of the hands (combined p=8.46×10−7) in all three
cohorts combined. When we categorized the participants of the TwinsUK
and the Chingford study into two groups: people who had at least two
joints of hands affected, deﬁned by KL 2, vs individuals who didn’t have
any hand’s joints affected, the minor allele was associated with a 33%
reduction of risk in the development of hand OA (p = 0.0002). The risk
was further reduced to 41% if the cases are deﬁned as at least three
joints affected (p = 0.00001).
Conclusions: This genome-wide scan identiﬁed a signiﬁcant association
between OA and a novel locus which has a potential role in transcriptional
regulation of calcitonin. This ﬁnding provides insight into previously un-
known genetic mechanisms in the development of hand OA.
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Purpose: Subchondral bone has attracted attention as a potential source
of pain in knee OA in part because of its intimate relationship to overlying
cartilage and its load bearing function. With full thickness cartilage
defects, exposed bone may be more likely to generate joint pain during
contact and weightbearing activity. We hypothesized that (1) increased
%denuded bone in OA knees is associated with increased pain and
(2) greater %denuded bone predicts incident frequent knee pain.
Methods: All participants had knee OA by deﬁnite osteophytes. Axial
and double oblique coronal SPGRwe sequences were acquired on a
1.5T or a 3T scanner. Images were processed with proprietary software
(Chondrometrics). Manual segmentation by trained readers was used
to compute total area of subchondral bone, cartilage surface area, and
cartilage-covered and denuded areas of bone for the medial tibia, lateral
tibia, weightbearing medial and lateral femur, and patella. Pain severity
was assessed with a knee-speciﬁc 100mm VAS for pain in the past
week. Frequent knee pain was deﬁned as pain in or around the knee
for most days in the past month. To test hypothesis 1, we used median
quantile regression to determine the increase in median pain score per
10% increase in denuded bone, analyzing the more painful knee. To test
hypothesis 2, we used logistic regression with GEE to estimate the odds
ratio (OR) per 10% increase in denuded bone at baseline for baseline-
to-2 year incident frequent knee pain. Analyses were adjusted for age,
gender, BMI, K/L grade, and bone edema score.
Results: 184 participants (age 66, BMI 30, 78% women) made up the
sample for hypothesis 1. As in Table 1, greater %denuded bone in the
noted medial surfaces was associated with increased median pain score.
176 knees in 119 persons (age 68, BMI 29, 74% women) did not have
frequent knee pain at baseline and made up the sample for hypothesis 2.
Of the 176 knees, 53 developed frequent knee pain over the next 2 years.
As in Table 2, greater %denuded bone at baseline was associated with
an increase in the adjusted odds for incident frequent knee pain.
Conclusions: Greater %denuded bone was associated with greater knee
pain severity. In knees without frequent pain at baseline, %denuded bone
predicted incident frequent knee pain. These results support that the
exposure of subchondral bone may be a source of pain in knee OA.
